XML 50 R36.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Revenues - Revenues Disaggregated by Significant Customer (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 28, 2018 | Sep. 29, 2017 | Sep. 28, 2018 | Sep. 29, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |
Revenues | $ 225,397 | $ 152,510 | $ 625,224 | $ 332,405
Revenue | Customer Concentration Risk |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |
Percent of total revenues | 100.00% | 100.00% | 100.00% | 100.00%
Ipsen |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |
Revenues | $ 57,186 | $ 50,680 | $ 145,038 | $ 60,704
Ipsen | Revenue | Customer Concentration Risk |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |
Percent of total revenues | 25.00% | 33.00% | 23.00% | 18.00%
Caremark L.L.C. |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |
Revenues | $ 30,707 | $ 20,272 | $ 83,516 | $ 52,526
Caremark L.L.C. | Revenue | Customer Concentration Risk |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |
Percent of total revenues | 14.00% | 13.00% | 13.00% | 16.00%
Affiliates of McKesson Corporation |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |
Revenues | $ 26,597 | $ 14,575 | $ 71,249 | $ 38,699
Affiliates of McKesson Corporation | Revenue | Customer Concentration Risk |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |
Percent of total revenues | 12.00% | 10.00% | 11.00% | 12.00%
Diplomat Specialty Pharmacy |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |
Revenues | $ 17,946 | $ 20,460 | $ 56,568 | $ 62,909
Diplomat Specialty Pharmacy | Revenue | Customer Concentration Risk |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |
Percent of total revenues | 8.00% | 13.00% | 9.00% | 19.00%
Accredo Health, Incorporated |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |
Revenues | $ 20,677 | $ 13,445 | $ 58,677 | $ 36,504
Accredo Health, Incorporated | Revenue | Customer Concentration Risk |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |
Percent of total revenues | 9.00% | 9.00% | 9.00% | 11.00%
Others, individually less than 10% of Total revenues for all periods presented |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |
Revenues | $ 72,284 | $ 33,078 | $ 210,176 | $ 81,063
Others, individually less than 10% of Total revenues for all periods presented | Revenue | Customer Concentration Risk |  |  |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |  |  |
Percent of total revenues | 32.00% | 22.00% | 35.00% | 24.00%

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=exel_IpsenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=exel_CaremarkL.L.C.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=exel_OtherCustomersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |